Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin versus rivaroxaban for venous thromboembolism prevention after primary total hip or knee arthroplasty
ChiCTR2400092488Phase 4Not yet recruiting
- Sponsor
- Department of Orthopedics, the First Affiliated Hospital of Xinjiang Medical University
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin and rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Department of Orthopedics, the First Affiliated Hospital of Xinjiang Medical University. Primary endpoints: Incidence of symptomatic venous thromboembolism and Healthcare resource utilization. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
aspirinrivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR2400092488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092488.